Media Resources

Date	Title
Apr 08, 2021	Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
Apr 05, 2021	GBT Announces New Employment Inducement Grants
Mar 18, 2021	GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors
Mar 16, 2021	GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
Mar 08, 2021	GBT Announces New Employment Inducement Grants

Media and Investor Contact

Steven Immergut
SVP, Head of Corporate Communications and Investor Relations
650-410-3258
simmergut@gbt.com